权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Combined Cognitive-Behavioral and Pharmacological Continuation and Maintenance Treatment of Recurrent Depression

复发性抑郁症的认知行为和药理学联合延续和维持治疗

基本信息

批准号：
15048089
负责人：
Professor Dr. Martin Hautzinger
金额：
--
依托单位：
Fakultät Soziale Arbeit, Bildung und Pflege
依托单位国家：
德国
项目类别：
Clinical Trials
财政年份：
2005
资助国家：
德国
起止时间：
2004-12-31 至 2016-12-31
项目状态：
已结题

来源：
https://gepris.dfg.de/gepris/projekt/15048089?language=en
关键词：
Combined Cognitive Behavioral Pharmacological Continuation

项目摘要

While recurrent depression is an established indicator for pharmacological maintenance treatment, empirical support for the long-term benefit of additional cognitive-behavioral therapy in continuation or maintenance treatment is lacking. The major goal of the study is to compare the long-term outcome of cognitive-behavioural maintenance therapy (CBMT) plus pharmacological continuation/maintenance treatment (treatment as usual, TAU) versus manualized psychoeducation (MAPE) plus TAU for out-patients with recurrent depression in a multi-centre, controlled, randomised trial. Patients meeting the following criteria were included: diagnosis of recurrent depressive disorder (≥ 3 major depressive episodes, MDE), currently in remission; complete remission over 8 weeks after acute treatment of MDE; at least one index depressive episode in the 12 months prior to the intervention. Exclusion criteria were: organic disorder; psychological / behavioural disorders caused by psychotropic substances; schizophrenia; schizoaffective disorder; bipolar depression; moderate to severe mental retardation; acute suicidality; severe comorbid medical condition. Patients meeting the inclusion criteria were randomly assigned to one of the two conditions (CBMT plus TAU or MAPE plus TAU). Currently, 186 patients have been recruited from 12 outpatient clinics of psychiatric hospitals and psychological departments in the Rhine-Main region and Thuringia. Funding of the trial presently covers an assessment of the effects of both treatment forms on the occurrence of relapse/recurrence of MDE for a period of only one year following treatment. There are no such long-term follow-ups of large and well controlled trails available. But in recurrent depression long-term relapse prevention is the most relevant outcome criteria.

虽然复发性抑郁症是药物维持治疗的既定指标，但缺乏对继续或维持治疗中额外认知行为治疗的长期益处的经验支持。该研究的主要目的是在一项多中心、对照、随机试验中比较认知行为维持治疗（CBMT）加药物继续/维持治疗（常规治疗，TAU）与手动心理教育（MAPE）加TAU治疗复发性抑郁症门诊患者的长期结果。符合以下标准的患者包括：诊断为复发性抑郁症（≥3次重度抑郁发作，MDE），目前处于缓解期；急性MDE治疗后8周内完全缓解；干预前12个月内至少有一次抑郁发作。排除标准为：器质性疾病；精神药物引起的心理/行为障碍；精神分裂症;分裂情感性障碍;双相抑郁;中度至重度智力迟钝；急性自杀倾向;严重的合并症。符合纳入标准的患者被随机分配到两种情况（CBMT + TAU或MAPE + TAU）中的一种。目前，已从莱茵-美因地区和图林根州精神病院和心理科的12个门诊诊所招募了186名患者。目前，该试验的资金用于评估两种治疗方式在治疗后仅一年内对MDE复发/复发的影响。目前还没有大规模的、控制良好的长期跟踪试验。但对于复发性抑郁症，长期预防复发是最相关的预后标准。